With a market capitalization (market cap) of $2.08B — a measure of how much the company is worth — Nanobiotix S.A. is the 2084th most valuable company in Healthcare as of August 18, 2026. Shares trade at $41.08, down +2.31% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Visit websiteAs of August 18, 2026, Nanobiotix S.A. (NBTX) is worth $2.08B — this is its market capitalization, the total value of all its outstanding shares.
Nanobiotix S.A.’s market cap is $2.08B, which ranks it #2084 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Nanobiotix S.A. (NBTX) shares trade at $41.08, down 2.31% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025